Split-Face Study Using a 1,927-nm Thulium Fiber Fractional Laser to Treat Photoaging and Melasma in Asian Skin


  • The authors have indicated no significant interest with commercial supporters.

Address correspondence and reprint requests to: Sung Eun Chang, MD, PhD, Department of Dermatology and Research Institute of Dermatology, University of Ulsan College of Medicine, Asan Medical Center, 388–1 Pungnapdong Songpagu, Seoul, 138–736 Korea, or e-mail: csesnumd@gmail.com



Although the 1,927-nm thulium fiber fractional laser is effective and safe for treating photoaging, clinical data regarding this modality remain limited.


To investigate the efficacy and safety of the 1,927-nm thulium fiber fractional laser for treating photoaging and melasma in Asians.


Twenty-five participants received three laser treatments (at 3-week intervals) on the half of the face with more-severe photoaging and melasma. Independent investigators evaluated clinical improvement 2 and 6 months after the final treatment. Improvement in melasma was evaluated using the Melasma Area and Severity Index. Subjective satisfaction rates were also evaluated. Adverse events were assessed, and pain was scored using a visual analog scale (VAS). Histologic changes were observed using immunohistochemical staining.


Clinical improvement of photodamaged facial skin was remarkable on the treatment side. Most participants reported that their subjective satisfaction rate was greater than slight satisfaction. Downtime for healing required approximately 1 week. No severe adverse events occurred. Mean VAS score during treatment was 4.8. Collagen regeneration and melanin decrease were observed histologically.


The 1,927-nm thulium fiber fractional laser is a safe, effective treatment for photoaging and melasma in Asians.